share_log

Wedbush Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $2

Wedbush Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $2

Wedbush 将Unity 生物技术评级下调至中性,将目标股价下调至2美元
Benzinga ·  2023/06/26 06:05

Wedbush analyst Andreas Argyrides downgrades Unity Biotechnology (NASDAQ:UBX) from Outperform to Neutral and lowers the price target from $3 to $2.

Wedbush分析师安德烈亚斯·阿吉里德斯将Unity Biochnology(纳斯达克股票代码:UBX)的评级从跑赢大盘下调至中性,并将目标股价从3美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发